CA2549641A1 - Mitotic kinesin inhibitors - Google Patents
Mitotic kinesin inhibitors Download PDFInfo
- Publication number
- CA2549641A1 CA2549641A1 CA002549641A CA2549641A CA2549641A1 CA 2549641 A1 CA2549641 A1 CA 2549641A1 CA 002549641 A CA002549641 A CA 002549641A CA 2549641 A CA2549641 A CA 2549641A CA 2549641 A1 CA2549641 A1 CA 2549641A1
- Authority
- CA
- Canada
- Prior art keywords
- chloro
- quinazolin
- fluorophenyl
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53137203P | 2003-12-19 | 2003-12-19 | |
| US60/531,372 | 2003-12-19 | ||
| PCT/US2004/042070 WO2005065183A2 (en) | 2003-12-19 | 2004-12-15 | Mitotic kinesin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2549641A1 true CA2549641A1 (en) | 2005-07-21 |
Family
ID=34748759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002549641A Abandoned CA2549641A1 (en) | 2003-12-19 | 2004-12-15 | Mitotic kinesin inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070060601A1 (https=) |
| EP (1) | EP1696927A4 (https=) |
| JP (1) | JP2007517071A (https=) |
| CN (1) | CN1893951A (https=) |
| AU (1) | AU2004311737A1 (https=) |
| CA (1) | CA2549641A1 (https=) |
| WO (1) | WO2005065183A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007536239A (ja) * | 2004-05-06 | 2007-12-13 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CA2630117A1 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP2079739A2 (en) * | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN107417628A (zh) * | 2017-06-28 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 二芳基喹唑啉酮类化合物、其制备方法及其医药用途以及包含该类化合物的药物组合物 |
| CN110041272B (zh) * | 2019-05-29 | 2020-10-30 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯苯基)喹唑啉-4(3h)-酮类衍生物及其制备方法和用途 |
| CN110041273B (zh) * | 2019-05-29 | 2020-10-20 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯-4-甲基苯基)喹唑啉-4(3h)-酮类化合物及其医药用途 |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257397A (en) * | 1963-07-26 | 1966-06-21 | Rexall Drug Chemical | Substituted 2, 3-dihydro-4(1h)-quinazolinones |
| US3231572A (en) * | 1963-08-05 | 1966-01-25 | Miles Lab | 3-substituted-4-quinazolones |
| DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
| US3463778A (en) * | 1967-01-13 | 1969-08-26 | Squibb & Sons Inc | Substituted 2,3-dihydro-4(1h)-quinazolinones |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3717034A1 (de) * | 1987-05-21 | 1988-12-08 | Basf Ag | Photopolymerisierbare aufzeichnungsmaterialien sowie photoresistschichten und flachdruckplatten auf basis dieser aufzeichnungsmaterialien, sowie neue chinazolon-4-verbindungen |
| JP2000501086A (ja) * | 1995-11-24 | 2000-02-02 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | ピリドピリミジン |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6479499B1 (en) * | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| EP1513820A4 (en) * | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
-
2004
- 2004-12-15 CA CA002549641A patent/CA2549641A1/en not_active Abandoned
- 2004-12-15 CN CNA2004800376917A patent/CN1893951A/zh active Pending
- 2004-12-15 US US10/582,823 patent/US20070060601A1/en not_active Abandoned
- 2004-12-15 AU AU2004311737A patent/AU2004311737A1/en not_active Abandoned
- 2004-12-15 JP JP2006549289A patent/JP2007517071A/ja not_active Withdrawn
- 2004-12-15 WO PCT/US2004/042070 patent/WO2005065183A2/en not_active Ceased
- 2004-12-15 EP EP04814275A patent/EP1696927A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005065183A3 (en) | 2005-09-29 |
| JP2007517071A (ja) | 2007-06-28 |
| CN1893951A (zh) | 2007-01-10 |
| EP1696927A2 (en) | 2006-09-06 |
| AU2004311737A1 (en) | 2005-07-21 |
| WO2005065183A2 (en) | 2005-07-21 |
| US20070060601A1 (en) | 2007-03-15 |
| EP1696927A4 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7622468B2 (en) | Mitotic kinesin inhibitors | |
| US20050228003A1 (en) | Mitotic kinesin inhibitors | |
| US20070060601A1 (en) | Mitotic kinesin inhibitors | |
| CA2465491A1 (en) | Mitotic kinesin inhibitors | |
| AU2004305069C1 (en) | Mitotic kinesin inhibitors | |
| CA2508956A1 (en) | Mitotic kinesin inhibitors | |
| CA2485343A1 (en) | Mitotic kinesin inhibitors | |
| US20080102068A1 (en) | Mitotic Kinesin Inhibitors | |
| CA2468266A1 (en) | Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors | |
| CA2483627A1 (en) | Mitotic kinesin inhibitors | |
| US7632839B2 (en) | Mitotic kinesin inhibitors | |
| US20090124641A1 (en) | Mitotic Kinesin Inhibitors | |
| US7553838B2 (en) | Mitotic kinesin inhibitors | |
| EP1773326A2 (en) | Mitotic kinesin inhibitors | |
| US20070149553A1 (en) | Mitotic kinesin inhibitors | |
| CN1980663A (zh) | 有丝分裂驱动蛋白抑制剂的前体药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |